Conjugation of camptothecins to poly-(L-glutamic acid)

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 136-150

  Singer, Jack W ^a,b   De Vries, Peter ^a   Bhatt, Rama ^b   Tulinsky, John ^a   Klein, Peter ^b   Chun, L I ^b   Milas, Luka ^a   Lewis, Robert A ^b  

^a Cell Therapeutics Inc   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; POLYGLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DETERMINATION; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; TECHNOLOGY;

ANIMALIA; MURINAE;

EID: 0034509559     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07032.x     Document Type: Article

References (44)

1. Pharmacokinetics of high molecular weight agents
2. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
3. Phase I clinical and pharmacokinetic study of PK1 [N-(2- hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - Drug-polymer conjugates
4. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies
5. Topoisomerase I inhibitors: Review and update
6. Camptothecin and its analogs
7. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: A frequency-domain fluorescence spectroscopic study
8. Differential interactions of camptothecin lactone and carboxylate forms with human blood components
9. Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy
10. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: Relation to dose and toxicity
11. Phase I clinical and pharmacological studies of 20-(s)-camptothecin and 20-(s)-9-nitrocamptothecin as anticancer agents
12. Preferential binding of the carboxylate form of camptothecin by human serum albumin
13. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin
14. Treatment of malignant melanoma with camptothecin (NSC-1008800)
15. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880)
16. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer
17. The structure basis of camptothecin interactions with human serum albumin: Impact on drug stability
18. Reduced albumin binding promotes the stability and activity of topotecan in human blood
19. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: A pediatric oncology group study
20. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients
21. Phase I trial of the colloidal dispersion formulation of 9-amino-20(s)-camptothecin administered as a 72-hour continuous intravenous infusion
22. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks
23. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients
24. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma
25. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma
26. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer
27. 9-Aminocamptothecin and beyond: Preclinical and clinical studies
28. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs and mice
29. Camptothecin-20-PEG ester transport forms: The effect of spacer groups on antitumor activity
30. Camptothecin delivery systems: The antitumor activity of a camptothecin-20-O-polyethylene glycol ester transport form
31. Camptothecin delivery systems: Enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker
32. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate
33. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors
34. Reformulating paclitaxel
35. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor
36. Effect of molecular weight (MW) of n-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats
37. 123I-labelled n-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma
38. Poly(amino acid) copolymers as a potential soluble drug delivery system. 1. Pinocytic uptake and lysosomal degradation measured in vitro
39. Action of (s)-10-hydroxycamptothecin on P388 leukemia and distribution of the drug in mice
40. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity
41. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs
42. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin